What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?

Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.